key: cord-0947109-hth8f5sn authors: Hou, Tieying; Zeng, Weiqi; Yang, Minling; Chen, Wenjing; Ren, Lili; Ai, Jingwen; Wu, Ji; Liao, Yalong; Gou, Xuejing; Li, Yongjun; Wang, Xiaorui; Su, Hang; Wang, Jianwei; Gu, Bing; Xu, Teng title: Development and Evaluation of A CRISPR-based Diagnostic For 2019-novel Coronavirus date: 2020-02-23 journal: nan DOI: 10.1101/2020.02.22.20025460 sha: 04030bba3035a58c7725ae267973206f6eb6c0b4 doc_id: 947109 cord_uid: hth8f5sn Background: The recent outbreak of infections by the 2019 novel coronavirus (2019-nCoV), the third zoonotic CoV has raised great public health concern. The demand for rapid and accurate diagnosis of this novel pathogen brought significant clinical and technological challenges. Currently, metagenomic next-generation sequencing (mNGS) and reverse-transcription PCR (RT-PCR) are the most widely used molecular diagnostics. Methods: 2019-nCoV infections were confirmed in 52 specimens by mNGS. Genomic information was analyzed and used for the design and development of an isothermal, CRISPR-based diagnostic for this novel virus. The diagnostic performance of CRISPR-nCoV was assessed and compared across three technology platforms (mNGS, RT-PCR and CRISPR). Results: 2019-nCoVs sequenced in our study were conserved with the Wuhan strain, and shared certain genetic similarity with SARS-CoV. A high degree of variation in the level of viral RNA was observed in clinical specimens. CRISPR-nCoV demonstrated a near single-copy sensitivity and great clinical sensitivity with a shorter turn-around time than RT-PCR. Conclusion: CRISPR-nCoV presents as a promising diagnostic option for the emerging pathogen. Since the beginning of 2020, a surging number of pneumonia caused by infections of a novel 56 coronavirus (2019-nCoV) have been identified in China, especially Wuhan, a metropolitan 57 city with a population of over 10 million. [1, 2] In recent days, the outbreak has affected 58 multiple countries and caused worldwide impact. The epidemic of 2019-nCoV was first discovered by metagenomic next-generation 69 sequencing (mNGS) in which the novel virus was found to be a new pathogenic member of 70 the betacoronavirus genus but shared only about 79% in genetic similarity with SARS. [8, 9] 71 Currently, metagenomics and RT-PCR are two molecular approaches most commonly used 72 diagnostics for this novel virus. [13, 14] However, the diagnostic performance of different 73 molecular methods have not been investigated. 74 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is Here, to address this question and the expanding clinical needs, we developed CRISPR-nCoV, 78 a rapid assay for 2019-nCoV detection, and compared the diagnostic performance among 79 three different technological platforms: metagenomic sequencing, RT-PCR and CRISPR. To the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is The open reading frame (ORF) of Cas13a was synthesized after codon optimization. The Cas13a ORF was then cloned into expression vector Pc013 and transfected into E. 116 coli BL21, which were first grown at 37°C and incubated with IPTG at 16°C. Proteins were the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint 8 UAAG GUU-3') and ssRNA probe (5´-6-FAM-UUUU UC-BHQ1) were used for the 135 CRISPR detection following RPA amplification. 154 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is For the evaluation of LoD by the number of DNA copies, DNA of the 2019-nCoV plasmid 155 was purified and the concentration was determined by a Qubit (Thermo Fisher, 156 Massachusetts). The copy number concentration was then calculated based the weight and the 157 length of fragment. Serial dilution with nuclease-free water was done to achieve desired 158 concentrations. 2.5μl of extracted DNA at each titer was used as templates. Ten replicates 159 were performed at each data point near detection limit. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is 191 We seek to develop a rapid, highly sensitive and simple-to-use assay by taking advantage 192 of both the polymerase-mediated DNA amplification by RPA and the CRISPR/Cas-mediated 193 enzymatic signal amplification for improved sensitivity (Figure 2A) . Moreover, the 194 All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint 1 isothermal nature of such an assay abolished the demand for sophiscated instruments such as 195 thermal cyclers as for PCR-based assays. Based on the three potential target sequences we identified, multiple sets of RPA primers 197 and CRISPR gRNAs were designed and screened. Among these, the set that targeted Orf1ab 198 showed the best overall performance of sensitivity and specificity, and therefore, was used to 199 develop CRISPR-nCoV in this study for further evaluation (data not shown). 200 We then sought to determine its analytical sensitivity by serial dilution at various 201 concentrations. As shown in Figure 2B , CRISPR-nCoV consistently detected 7.5 copies of 202 2019-nCoV in all 10 replicates, 2.5 copies in 6 out of 10 , and 1.25 copies in 2 out of 10 runs. These data indicate that CRISPR-nCoV had a near single-copy sensitivity. To confirm its 204 specificity, we tested CRISPR-nCoV with DNA from human cells as well as a panel of the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint 1 opportunity to take advantage of both the sensitivity of an isothermal assay and the specificity 279 of the CRISPR system. [21] As we demonstrated in this study, CRISPR-nCoV was able to 280 deliver comparable sensitivity and specificity as mNGS within as short as 40 minutes. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is A novel coronavirus from patients with pneumonia in China Early Transmission Dynamics in Wuhan, China Coronavirus-Infected Pneumonia Nowcasting and forecasting the potential domestic and international 298 spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study INVITED REVIEW Quantification of mRNA using real-time reverse transcription PCR 322 (RT-PCR): trends and problems CRISPR-Cas: evolution of an RNA-based adaptive immunity system in 324 prokaryotes CRISPR-Cas12a target 326 binding unleashes indiscriminate single-stranded DNase activity CRISPR-based Rapid and Ultra-sensitive Diagnostic Test for 329 Mycobacterium Tuberculosis. Emerging Microbes & Infections Programmed DNA 331 destruction by miniature CRISPR-Cas14 enzymes Field-deployable viral diagnostics using CRISPR-Cas13. Science A novel coronavirus emerging in China-key 337 questions for impact assessment Field-deployable viral diagnostics using 339 CRISPR-Cas13 No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint (which was not peer-reviewed) is All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint (which was not peer-reviewed) is . https://doi.org/10.1101/2020.02.22.20025460 doi: medRxiv preprint